ScreenerHero

AVTXAvalo Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · avalotx.com
19.83USD-4.43%Mkt Cap: 1.06B $P/E: —

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.06B $
Enterprise Value662.91M $
Revenue (TTM)59.00K $
Gross Profit59.00K $
Net Income (TTM)-78.26M $
Revenue/Share0.0020 USD
Last Price19.83 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees33
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.53
PEG—
EV/EBITDA-7.26
EV/Revenue11235.80
P/S18016.04
P/B2.34
EPS (TTM)-4.21
EPS (Forward)-2.63
52W Range
8.41072% of range24.27
52W High24.27 USD
52W Low8.410 USD
Profitability
Gross Margin100.00%
Oper. Margin-154847.45%
EBITDA Margin0.00%
Profit Margin-132642.37%
ROE-94.23%
ROA-67.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.46M $
CapEx (TTM)—
FCF Margin-39442.37%
FCF Yield-2.19%
Net Debt-400.03M $
Net Debt/EBITDA4.38
Balance Sheet
Debt/Equity0.00
Current Ratio19.31
Quick Ratio18.94
Book Value/Sh8.481 USD
Cash/Share7.464 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:240
Split DateDec 29, 2023
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)44.15 USD
Upside (mean)+122.7%
Target Range30.00 USD – 60.00 USD
$30.00+122.7% to mean$60.00
# Analysts13
Ownership
Shares Out.53.63M
Float40.15M
Insiders1.69%
Institutions133.12%
Short Interest
Short Ratio11.7d
Short % Float24.52%
Short % Out.24.48%
Shares Short12.95M
Short (prev mo.)12.31M
Technical
SMA 5018.24 (+8.7%)
SMA 20016.71 (+18.7%)
Beta0.79
S&P 52W Chg18.16%
Avg Vol (30d)786.77K
Avg Vol (10d)693.33K
Technical Indicators
RSI (14)55.8
MACD0.5087
MACD Signal0.4355
MACD Hist.+0.0732
BB Upper20.64 USD
BB Middle19.13 USD
BB Lower17.63 USD
BB Width15.73%
ATR (14)1.137 USD
Vol Ratio (20d)0.77x